KANSAS CITY HEART RHYTHM SYMPOSIUM 2017
August 12-13, 2017 | KC Marriott Downtown

Welcome to Kansas City Heart Rhythm Symposium 2017

The Kansas City Heart Rhythm Symposium is the first EP-focused medical  education event for the neighboring four state regions. A variety of topics will provide  specialists and generalists an update on the evolution of disease  processes, diagnostic tools, therapeutic strategies and ethical issues  in the advancement of patient care.

Course Director

Dr L smaller file-1

Dhanunjaya Lakkireddy, MD, FACC, FHRS
University of Kansas Hospital
Kansas City, KS

Professor of Internal Medicine
Director – Center for Excellence in Atrial Fibrillation & Complex Arrhythmia Rx
Director – Electrophysiology Research
KU Cardiovascular Research Institute
Mid America Cardiology, Bloch Heart Rhythm Center
University of Kansas Hospital & Medical Center
Kansas City, KS

KU Pioneer in Electrophysiology Award Winner & Keynote Speaker

 
   
  
  
  
 
  
  
  
  
  
  
Sanjeev Saksena, MBBS, MD

 Sanjeev Saksena, MBBS, MD was born in Delhi, India in 1952. His early education was obtained in both India and Edinburgh, Scotland, graduated in Medicine from the All India Institute of Medical Sciences, New Delhi, specialized in Internal Medicine at SUNY, Stony Brook and Cardiology/Electrophysiology at the University of Miami Medical Center. In 1980 he established the first comprehensive cardiac electrophysiology program in New Jersey at the Newark Beth Israel Medical Center – UMDNJ Medical School in Newark. In his 37 year career in New Jersey, he has established and held institutional leadership positions in Adult Cardiac Electrophysiology at 4 institutions, Pediatric Electrophysiology at the Children’s Hospital of New Jersey, Adult Cardiology, Cardiovascular Research and Education and led the Cardiovascular Institute at Atlantic Health Systems (East). In 1982, he founded the Electrophysiology Research Foundation, the first stand alone non-profit private Research Foundation devoted solely to research and education in cardiac electrophysiology, which remains actively involved in this field for 35 years. He is currently Professor of Medicine at the Rutgers’-Robert Wood Johnson Medical School, New Jersey, Medical Director and Trustee of the Electrophysiology Research Foundation, and Founding Editor and Editor in Chief of the Journal of Interventional Cardiac Electrophysiology.

Dr. Saksena’s early experiences shaped his subsequent research career. As a medical student he worked on high altitude circulatory physiology with first mentor, Professor Sujoy B. Roy and later in residency and fellowship on myocardial function in acute myocardial infarction, electrophysiological studies in ventricular tachycardia under the guidance of Drs. Augustin Castellanos and Robert Myerburg and in 1981, co-authored the pivotal study on the posterior anatomic location of slow AV nodal pathway with Dr. Sung that led to the development of selective slow AV nodal pathway ablation. In his basic and clinical electrophysiologic laboratories in New Jersey, pioneering research studies in non-pharmacologic therapies for tachycardias established momentum in this new direction in antiarrhythmic therapy in the early 1980s. He published pivotal studies in experimental, technologic and early concept clinical investigations in the nascent fields of ventricular defibrillation and surgical and catheter ablation with laser and radiofrequency energy. His early proof of concept studies developed the technique of simultaneous bidirectional shocks culminating in the first successful human implant of an implantable defibrillator with a triple electrode system without a thoracotomy in 1987 and anti-tachycardia pacing as the first line of therapy for ventricular tachycardia in device algorithms. Their group examined the hemodynamics of ventricular tachycardia in man in the mid-1980s and in collaboration with Dr. Navin Nanda performed the first echocardiographic imaging studies to examine ventricular function in this arrhythmia.

Important clinical studies were led by this group such as the first pacemaker-defibrillator device investigation, newly developed transvenous endocardial defibrillation leads that are precursors of all such leads today, comparison of thoracotomy and transvenous defibrillator implant methods and the first report of defibrillation lead performance and failures. Other early Investigations in the next five years established the superiority of biphasic shocks in transvenous defibrillation, and subcutaneous thoracic electrode mapping of the chest, leading to the development of the active pectoral can electrode. The triple electrode configuration, biphasic shocks and pectoral can/ subcutaneous thoracic electrodes remain part of clinical defibrillator implant techniques in 2017.

An early investigator of Dr. Schienman’s technique of direct current catheter ablation of the AV junction in 1984, he became intrigued by the use of alternative energy sources for ablation and demonstrated the successful use of laser energy for ablation in AV nodal, AV reentrant and ventricular tachycardia and new catheter delivery methods of radiofrequency energy in the late 1980s.

In the 1990s their group turned their attention to device based therapies of atrial fibrillation, developed high frequency pacing for termination and dual site atrial pacing for prevention of atrial fibrillation. He pioneered the technique of dual site right atrial pacing and established its adjunctive role in long term management of drug refractory atrial fibrillation in combination with drug and ablative approaches.

Another important area of study involved study of the mechanisms in human atrial fibrillation. His early studies first reported in 1999 and reaffirmed in subsequent publications till 2005 promoted a bi-atrial origin of the arrhythmia, with drivers from multiple right and left atrial sites varying in complexity with AF subtypes, differing significantly from the prevailing concepts. Recent studies with advancing sophisticated mapping systems now support these ideas. These pioneering ideas were recognized with the grant of several patents for these therapeutic techniques. Recent studies examine the value of atrial resynchronization in atrial reverse remodeling and heart failure with preserved systolic function.

He has been a clinical trialist for three decades and has designed and executed major clinical trials at the NHLBI and for FDA approval of antiarrhythmic therapies. As a pioneering investigator, he became a key planner and held leadership roles in pivotal clinical trials in clinical electrophysiology such as AVID, AFFIRM, and MADIT 1. In 1998, he reported the key observation that implantable defibrillator recipients with decreased left ventricular function in the AVID trial derived superior survival benefit over antiarrhythmic drugs, an observation that drove generations of ICD trials for the next decade and remains a key criterion in current patient selection. More recently his interest in heart failure studies has focused on “diastolic” heart failure, development of the TOPCAT study and the impact of atrial fibrillation and antiarrhythmic interventions in this form of heart failure. He has been instrumental in development of practice guidelines for ICD therapy, standards for catheter ablation, nomenclature in defibrillation and tachycardia classification, and proposed the generic term “ICD” in 1987, which was adopted in scientific parlance.

Dr. Saksena has authored 350 peer reviewed journal articles, over 425 abstracts, 86 book chapters.co- edited 6 textbooks, 10 journal supplements and three reference textbooks. He has been a member of NIH study sections, and chaired several clinical trials including DAPPAF, HIPPAF, ICE-CHIP, CAFÉ AMIGO and ENTICED-AF. In 1990, in conjunction with Berndt Luderitz, he coined the concept of Interventional Cardiac Electrophysiology as a defined scientific discipline with quadrennial international meetings devoted to cutting-edge research in this subject over the next 20 years. In 1996, he founded the Journal of Interventional Cardiac Electrophysiology devoted to original research in this area, cementing this new scientific discipline. Today, interventional cardiac electrophysiology dominates the clinical activities of practitioners of cardiac electrophysiology worldwide.

He has been a consultant to governmental and private organizations, a Founding member of the European Cardiac Arrhythmia Society, co-founder of the Indian Heart Rhythm Society and has a long record of public service. He founded and led the Government Relations Committee at the national society, established early health economic investigations, payment codes and standards in electrophysiology and health care advocacy for practitioners in this specialty. He served as President of the North American Society of Pacing and Electrophysiology in 1998, whose restructuring into the Heart

Rhythm Society and global strategic direction was initiated during his tenure. He has been a recipient of Distinguished Scientific Achievement awards from numerous international societies. His trainees now supervise electrophysiology programs or are cardiology faculty members in three continents. He has been annually included in the listing of “America’s Top Cardiologists”, New Jersey Top Doctors and recognized by the cardiovascular device industry for these contributions.

He is an internationally renowned scientist and widely sought speaker and maintains a global presence in the field. Dr. Saksena’s breadth and depth of pioneering contributions have been instrumental in founding and developing interventional cardiac electrophysiology by advancing new concepts and techniques that have become part of current day practice. His pivotal clinical investigations, enormous energy in disseminating scientific knowledge in this field worldwide, and expanding the horizons of electrophysiologic therapies in cardiac disease have led colleagues to refer to him as a “Founder of modern electrophysiology”. He remains active in clinical practice and scientific investigation in New Jersey.

Copyright © KCHRS. All Rights Reserved. Privacy Policy
Site Created by KC Web Specialists, LLC.